Clinical Trials Logo

Stage III/IV Melanoma clinical trials

View clinical trials related to Stage III/IV Melanoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT03132675 Active, not recruiting - Clinical trials for Stage III/IV Melanoma

Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment

Keynote-695
Start date: October 3, 2017
Phase: Phase 2
Study type: Interventional

Keynote 695 is Phase 2 study of intratumoral tavokinogene telseplasmid (tavo; pIL-12) Electroporation (EP) plus IV Pembrolizumab. Eligible patients will be those with pathological diagnosis of unresectable or metastatic melanoma who are progressing or have progressed on either pembrolizumab or nivolumab.

NCT ID: NCT02857569 Completed - Clinical trials for Stage III/IV Melanoma

A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma

NIVIPIT
Start date: December 5, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The study aims to evaluate the 6 month-treatment tolerance defined as the immune related grade 3-4 adverse event-free survival of the combination therapy IT ipilimumab + IV nivolumab. The IV ipilimumab + IV nivolumab (same doses than in Phase I) arm will be used as an internal control to interpret the results obtained in the IT ipilimumab arm.